Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4037/ajcc2022643 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Institute of Neuroscience - UCLouvain, Brussels, Belgium.
Background: In AD, tauopathy and atrophy start in the mesiotemporal lobe, including the amygdala-hippocampal complex. Until recently, subnuclei and subfields within these structures were indistinguishable in-vivo. FreeSurfer 7.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Baehwa University, Seoul, Seoul, Korea, Republic of (South).
Background: It is difficult to predict of long-term treatment response of AD to medical treatment when starting medication. We explored EEG brain connectivity as a potential biomarker for long-term medication outcomes in patients with AD.
Methods: Resting-state EEG was recorded from a total of 56 AD patients (mean age = 73.
Background: Tangle burden, one of the hallmarks of Alzheimer's Disease, is thought to accumulate and spread throughout the brain in a distinctive pattern starting from the entorhinal cortex following Braak stages as characterized in neuropathological studies. Longitudinal tau PET allows us to investigate in vivo the tau spread in an individual and substantial heterogeneity has been observed in the pattern of tau spread. In this analysis, we examine the statistical power of tau PET measurements in tracking disease progression using data from the ADNI cohort.
View Article and Find Full Text PDFBackground: Metabolomics captures net influences of exposome, diet, gut microbiome, and genome, informing about individuality and how we respond to interventions. Applications of metabolomics in pharmacology are starting to enable a Systems Pharmacology approach, where the outcome of a treatment is considered to evolve from effects on complex molecular networks, enabling insights into response variations. We bring the power of these approaches to the study of the MIND, a Mediterranean DASH diet for prevention of cognitive decline.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: Sleep disturbance is common and distressing for people with dementia, with no known safe, effective treatments. We previously developed and delivered DREAMS-START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives), a multimodal non-pharmacological intervention, and demonstrated feasibility and acceptability. This randomised controlled trial (RCT) aimed to establish whether DREAMS-START is clinically-effective in reducing sleep disturbances in people with dementia at home after 8 months compared to usual care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!